Uterine Fibroid Risk Factors: What Increases Your Chances?

Uterine fibroids (leiomyomas) are benign smooth muscle tumors affecting up to 70–80% of women by age 50. While exact etiology is multifactorial, established risk factors include:

Established Risk Factors

Factor	Details
Age	Peak incidence 30s–40s; shrink post-menopause (estrogen/progesterone dependent)
Race/Ethnicity	Black women: 2–3x higher incidence, earlier onset, larger/more numerous fibroids, more severe symptoms
Family History	First-degree relative with fibroids → 2–3x increased risk; genetic susceptibility (MED12, HMGA2, FH mutations)
Obesity (BMI ≥30)	Adipose tissue aromatizes androgens → estrogen; also insulin/IGF-1 pathways
Nulliparity / Late First Birth	Never pregnant or first pregnancy >30–35 increases risk; parity is protective
Early Menarche	<10–11 years → longer estrogen exposure
Vitamin D Deficiency	Strong epidemiologic link; VDR polymorphisms affect fibroid growth
Hypertension	Independent association; vascular/angiogenic mechanisms
Dietary Factors	Red meat, ham → ↑ risk; green vegetables, fruit, dairy → ↓ risk
Alcohol	Beer specifically associated in some studies
PCOS	Hyperandrogenism, insulin resistance, anovulation → unopposed estrogen
EDC Exposure	Endocrine-disrupting chemicals (phthalates, BPA, organochlorines) — emerging evidence

Protective Factors

• Multiparity (especially full-term pregnancies)
• Combined oral contraceptives (long-term use)
• DMPA (depot medroxyprogesterone acetate)
• Smoking (paradoxically protective in some studies — not a recommendation)

Clinical Perspective

Risk factors ≠ destiny. Many women with multiple risk factors never develop symptomatic fibroids; some with none do. Risk factors inform surveillance awareness, not prediction.

When to Discuss with Your Doctor

• Heavy/prolonged menstrual bleeding
• Pelvic pressure/pain
• Urinary frequency, constipation
• Reproductive concerns (infertility, recurrent loss)
• Incidental finding on imaging

Management options range from watchful waiting to medical therapy (GnRH agonists, SPRMs, tranexamic acid) to minimally invasive procedures (UAE, myomectomy, hysterectomy).